132 related articles for article (PubMed ID: 18324648)
21. Immunohistochemical level of unsulfated chondroitin disaccharides in the cancer stroma is an independent predictor of prostate cancer relapse.
Sakko AJ; Butler MS; Byers S; Reinboth BJ; Stahl J; Kench JG; Horvath LG; Sutherland RL; Stricker PD; Henshall SM; Marshall VR; Tilley WD; Horsfall DJ; Ricciardelli C
Cancer Epidemiol Biomarkers Prev; 2008 Sep; 17(9):2488-97. PubMed ID: 18768520
[TBL] [Abstract][Full Text] [Related]
22. Urokinase-plasminogen-activator receptor expression in disseminated tumour cells in the bone marrow and peripheral blood of patients with clinically localized prostate cancer.
Thomas C; Wiesner C; Melchior SW; Schmidt F; Gillitzer R; Thüroff JW; Pfitzenmaier J
BJU Int; 2009 Jul; 104(1):29-34. PubMed ID: 19154451
[TBL] [Abstract][Full Text] [Related]
23. The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer.
Wilt TJ; Brawer MK; Barry MJ; Jones KM; Kwon Y; Gingrich JR; Aronson WJ; Nsouli I; Iyer P; Cartagena R; Snider G; Roehrborn C; Fox S
Contemp Clin Trials; 2009 Jan; 30(1):81-7. PubMed ID: 18783735
[TBL] [Abstract][Full Text] [Related]
24. Longterm followup assessment of a HER2/neu peptide (E75) vaccine for prevention of recurrence in high-risk prostate cancer patients.
Gates JD; Carmichael MG; Benavides LC; Holmes JP; Hueman MT; Woll MM; Ioannides CG; Robson CH; McLeod DG; Ponniah S; Peoples GE
J Am Coll Surg; 2009 Feb; 208(2):193-201. PubMed ID: 19228530
[TBL] [Abstract][Full Text] [Related]
25. Prognostic significance of immunohistochemical expression of the HER-2/neu oncoprotein in bone metastatic prostate cancer.
Nishio Y; Yamada Y; Kokubo H; Nakamura K; Aoki S; Taki T; Honda N; Nakagawa A; Saga S; Hara K
Urology; 2006 Jul; 68(1):110-5. PubMed ID: 16806433
[TBL] [Abstract][Full Text] [Related]
26. Radical prostatectomy for high-risk prostate cancer: biochemical outcome.
Kawamorita N; Saito S; Ishidoya S; Ito A; Saito H; Kato M; Arai Y
Int J Urol; 2009 Sep; 16(9):733-8. PubMed ID: 19674167
[TBL] [Abstract][Full Text] [Related]
27. Expression of androgen receptor through androgen-converting enzymes is associated with biological aggressiveness in prostate cancer.
Wako K; Kawasaki T; Yamana K; Suzuki K; Jiang S; Umezu H; Nishiyama T; Takahashi K; Hamakubo T; Kodama T; Naito M
J Clin Pathol; 2008 Apr; 61(4):448-54. PubMed ID: 17720776
[TBL] [Abstract][Full Text] [Related]
28. Oncologic outcome and patterns of recurrence after salvage radical prostatectomy.
Paparel P; Cronin AM; Savage C; Scardino PT; Eastham JA
Eur Urol; 2009 Feb; 55(2):404-10. PubMed ID: 18639970
[TBL] [Abstract][Full Text] [Related]
29. Low stroma androgen receptor level in normal and tumor prostate tissue is related to poor outcome in prostate cancer patients.
Wikström P; Marusic J; Stattin P; Bergh A
Prostate; 2009 Jun; 69(8):799-809. PubMed ID: 19189305
[TBL] [Abstract][Full Text] [Related]
30. Distant metastases from prostatic carcinoma express androgen receptor protein.
Hobisch A; Culig Z; Radmayr C; Bartsch G; Klocker H; Hittmair A
Cancer Res; 1995 Jul; 55(14):3068-72. PubMed ID: 7541709
[TBL] [Abstract][Full Text] [Related]
31. Pretreatment prostate-specific antigen velocity is associated with development of distant metastases and prostate cancer mortality in men treated with radiotherapy and androgen-deprivation therapy.
Palma D; Tyldesley S; Pickles T;
Cancer; 2008 May; 112(9):1941-8. PubMed ID: 18338814
[TBL] [Abstract][Full Text] [Related]
32. Androgen receptor as a potential sign of prostate cancer metastasis.
Lévesque MH; El-Alfy M; Cusan L; Labrie F
Prostate; 2009 Nov; 69(15):1704-11. PubMed ID: 19670238
[TBL] [Abstract][Full Text] [Related]
33. Preclinical testing of a peptide-based, HER2/neu vaccine for prostate cancer.
Woll MM; Hueman MT; Ryan GB; Ioannides CG; Henderson CG; Sesterhan IA; Shrivasta S; McLeod DG; Moul JW; Peoples GE
Int J Oncol; 2004 Dec; 25(6):1769-80. PubMed ID: 15547716
[TBL] [Abstract][Full Text] [Related]
34. Captopril may reduce biochemical (prostate-specific antigen) failure following radical prostatectomy for clinically localized prostate cancer.
Ronquist G; Frithz G; Wang YH; Lindeborg T
Scand J Urol Nephrol; 2009; 43(1):32-6. PubMed ID: 18932051
[TBL] [Abstract][Full Text] [Related]
35. Expression of androgen and estrogen related proteins in normal weight and obese prostate cancer patients.
Gross M; Ramirez C; Luthringer D; Nepomuceno E; Vollmer R; Burchette J; Freedland SJ
Prostate; 2009 Apr; 69(5):520-7. PubMed ID: 19107851
[TBL] [Abstract][Full Text] [Related]
36. Utility of Bcl-2, P53, Ki-67, and caveolin-1 immunostaining in the prediction of biochemical failure after radical prostatectomy in a Japanese population.
Goto T; Nguyen BP; Nakano M; Ehara H; Yamamoto N; Deguchi T
Urology; 2008 Jul; 72(1):167-71. PubMed ID: 18384856
[TBL] [Abstract][Full Text] [Related]
37. Natural history of persistently elevated prostate specific antigen after radical prostatectomy: results from the SEARCH database.
Moreira DM; Presti JC; Aronson WJ; Terris MK; Kane CJ; Amling CL; Freedland SJ
J Urol; 2009 Nov; 182(5):2250-5. PubMed ID: 19758614
[TBL] [Abstract][Full Text] [Related]
38. Obesity and oncological outcome after radical prostatectomy: impact of prostate-specific antigen-based prostate cancer screening: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databases.
Freedland SJ; Sun L; Kane CJ; Presti JC; Terris MK; Amling CL; Moul JW; Aronson WJ
BJU Int; 2008 Sep; 102(8):969-74. PubMed ID: 18691175
[TBL] [Abstract][Full Text] [Related]
39. Quantitative RT-PCR analysis of estrogen receptor gene expression in laser microdissected prostate cancer tissue.
Walton TJ; Li G; McCulloch TA; Seth R; Powe DG; Bishop MC; Rees RC
Prostate; 2009 Jun; 69(8):810-9. PubMed ID: 19189301
[TBL] [Abstract][Full Text] [Related]
40. Mitochondrial DNA in serum of patients with prostate cancer: a predictor of biochemical recurrence after prostatectomy.
Ellinger J; Müller SC; Wernert N; von Ruecker A; Bastian PJ
BJU Int; 2008 Aug; 102(5):628-32. PubMed ID: 18410441
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
